

Anteo Live Investor Webcast – Monday 6 November

30 October 2017

Anteo Diagnostics Ltd (ASX: ADO) (“**Anteo**” or the “**Company**”) is pleased to host a live webcast to discuss the Company’s strategy with investors.

Chairman, Dr John Hurrell, will update investors and take questions on:

- The challenges of the last 12 months
- Strategy of the Company
- Goals of the Company
- Update on opportunities
- Board structure

A brief investor presentation will be made during the webcast prior to question time.

Webcast details:

Time: Monday 6 November 2017, 3:00pm (AEDT)

Webcast link:

<http://webcasting.boardroom.media/broadcast/59f28ea060ff344b8fcd8af2>

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

For more information, please visit www.anteodx.com